No Data
No Data
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 — GRI Bio,
GRI Bio Regains Compliance With Nasdaq
LA JOLLA, CA, July 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the tr
Express News | GRI Bio Shares Are Trading Higher After the Company Announced the Publication of Preclinical Data Demonstrating Its Lead Program GRI-0621 Reduced Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
Express News | GRI Bio Publishes Preclinical Data From Lead Program GRI-0621 In American Journal Of Respiratory And Critical Care Medicine
GRI Bio Announces Publication of Positive Preclinical Data From Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in miceCompare
No Data